CAHG-TBWA alliance will bring "disruption," says CEO

Share this article:

Omnicom's CAHG is partnering with sibling network TBWA/WorldHealth.

The partnership will give each agency a foothold in new territory—CAHG's global reach will now encompass its new partner's connections that include 36 countries and major regional hub offices, including those in Singapore and Hamburg, and TBWA will be better able to flex is strength in the US.

It's the latest in a series of recent transformations for CAHG, which last year became a go-to office for many of Omnicom's independent shops. Just two years ago, the agency, formerly known as Corbett Accel Healthcare Group, changed its name to reflect a new integrated communications network model that the company said would allow it to better leverage its positions in the New York and Chicago markets.

The Corbett agency dates to 1962 when its founder Frank Corbett opened his Chicago shop. His agency was the first to use direct mail feedback as a success indicator. BBDO purchased Corbett in 1972.

CAHG's accounts include Actelion, Alcon, Bayer HealthCare, Forest and Merck. TBWA's major accounts include Adidas, Apple, GSK, Pfizer and Roche.

CAHG chair and CEO Scott Cotherman said in a statement that the alliance will bring more than an expanded network.

“CAHG will benefit from two valuable proprietary practices: ‘Disruption,' which leads to finding new brand ideas for creating growth, and ‘Media Arts,' which is important for the delivery of behavior-changing messages in an increasingly multichannel communications world,” said Cotherman.

Share this article:
You must be a registered member of MMM to post a comment.

MM&M EBOOK: PATIENT ACCESS

Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Channel

Five things for pharma marketers to know: Monday, September 15

Five things for pharma marketers to know: ...

Pharma has sought 76 meetings with FDA over biosimilars; Gilead licenses Sovaldi to India generic drugmakers; Pfizer and Ranbaxy Lipitor lawsuit dismissed.

Liraglutide, aiming for new indication, gets new name

Liraglutide, aiming for new indication, gets new name

Why Novo Nordisk is choosing not to leverage Victoza's brand equity as it seeks a weight-loss indication for liraglutide.

Five things for pharma marketers to know: Friday, September 12

Five things for pharma marketers to know: Friday, ...

An FDA panel voted in favor of liraglutide for weight loss; Allergan investors backing an attempted takeover of the firm crossed a critical threshold; and 100 million health wearables are ...